(usual care vs amiodarone, 29% vs 36%; P ¼ .46). The difference remained nonsignificant even when we adjusted for covariates (age, sex, and length and complexity of surgery) with logistic regression (odds ratio, 1.5; P ¼ .28) and when we limited the sample to only patients undergoing coronary artery bypass grafting (usual care vs amiodarone, 27% vs 38%; P ¼ .36).
In contrast to Feng and colleagues, 4 we could not find a similar benefit in our patient population, putting the generalizability of their results in question. We would be pleased to learn from Feng and colleagues 4 whether they are continuing to study the use of topical amiodarone and also whether they are embarking on a larger trial to confirm the findings from their initial pilot study. Alternatively, have they begun to apply this therapy widely in their practice? On the basis of our experience, in light of its cost and the unclear benefits, we believe that the subject of topical amiodarone requires further study, limiting its routine use at present. My coauthors and I thank Beau and Kulik for their letter and for their efforts to address this significant problem in cardiothoracic surgery-specifically, postoperative atrial fibrillation. I applaud the investigators for their attempts to corroborate results from clinical studies such as ours, because this is a critical to the scientific The Editor welcomes submissions for possible publication in the Letters to the Editor section that consist of commentary on an article published in the Journal or other relevant issues. Authors should: Include no more than 500 words of text, three authors, and five references. Type with double-spacing. See http://jtcs.ctsnetjournals.org/ misc/ifora.shtml for detailed submission instructions. Submit the letter electronically via jtcvs.editorialmanager.com. Letters commenting on an article published in the JTCVS will be considered if they are received within 6 weeks of the time the article was published. Authors of the article being commented on will be given an opportunity of offer a timely response (2 weeks) to the letter. Authors of letters will be notified that the letter has been received. Unpublished letters cannot be returned.
process and ultimately leads to advances in the care of our patients. I would like to stress the importance of the application of the hydrogels, as outlined in our methods section, 1 because we believe that the concentration of the amiodarone and the complete exposure to the left atrial surface are key components to the results that we saw with this treatment. We are continuing to study the clinical efficacy of epicardial application of drug-releasing hydrogels, and we also recently completed a study on topical triamcinolone hydrogels in a similar clinical model. These results have recently been submitted to the Journal for consideration. Our ongoing early results strongly support the belief that epicardial delivery options may become a breakthrough therapy for preventing postoperative atrial fibrillation.
I encourage Beau and Kulik to continue their studies of postoperative atrial fibrillation, because their robust patient volume would readily support a prospective, randomized, controlled trial that could contribute significantly to the medical literature. The results in their study, however, I found very surprising because there was such a high rate of postoperative atrial fibrillation in the study group versus the control group (38% vs 27%), even if the covariates were adjusted. This may be attributable to the following reasons: (1) There was a limited study sample and an aging study group. (2) The mixture of amiodarone powder with COSEAL (Baxter Healthcare, Deerfield, Ill) was found to be time-consuming, and the preparation requires every particle to be dissolved into hydrogels, otherwise efficacy will be adversely affected. Of course, a number of issues may affect absorption of topical agents on the epicardial surface. On the basis of our multiple studies showing suboptimal coronary venous sinus blood concentration of amiodarone with topical amiodarone hydrogels, we are therefore currently embarking on a pivotal study with nanotechnology needle arrays for atrial epicardial amiodarone delivery to prevent postoperative atrial fibrillation.
Our team will continue to explore these and other options for the management of postoperative atrial fibrillation. We look forward to further contributions from Beau and Kulik, adding to the management algorithm of this difficult clinical problem.
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